Bharat Biotech finally names ICMR as co-owner in Covaxin patent filings

After reports claimed that filings in patent offices in India, the US, and Europe did not mention ICMR or its scientists, but only BBIL and its scientists, the Hyderabad-based biotechnology......

Over 30% Covaxin takers reported adverse events: Study

Nearly one-third of 926 individuals who received Bharat Biotech's anti-Covid vaccine Covaxin reported 'adverse events of special interest,' or AESI, according to a one-year follow up study......

50 million doses of Covaxin set to expire in 2023

Nearly 50 million doses of Bharat Biotech's COVID-19 vaccine, Covaxin lying with the firm are set to expire early next year as there are no takers owing to poor demand, company sources said.......

Govt denies pressuring Covaxin makers for early release of vaccine

The Union health ministry on Thursday termed as 'misleading' and 'fallacious' media reports which claimed that regulatory approval for COVID-19 vaccine Covaxin was rushed due to political pressure.......

Bharat Biotech starts Covaxin's at-risk manufacture

The first vaccine candidate will be an intra-muscular one, followed by intra-dermal and nasal ones, depending on test results, reports Sohini Das. Photograph: Kind courtesy Bharat Biotech  ......